Objective. The present study determined if vitamin D deficiency is a potential risk factor for increased carotid intima-media thickness (CIMT) in patients with rheumatoid arthritis (RA). 
Introduction
Increasing evidence indicates that low serum 25-hydroxy vitamin D (25-OHD) is associated with a higher frequency of cardiometabolic outcomes including type 2 diabetes mellitus, hypertension, and cardiovascular diseases (CVDs) in the general population (1, 2) . The National Health and Nutritional Examination Surveys (NHANES 2000∼2004) revealed that the frequency of CVDs including coronary heart disease, heart failure and peripheral vascular disease are significantly higher in adults with low 25-OHD levels (＜20 ng/mL) than those with high 25-OHD levels (≥30 ng/mL) (3) . In addition, limited data suggest that vitamin D supplementation may reduce the risk of CVDs (4, 5) and decrease mortality in elderly people (6) . Experimental evidence that vitamin D regulates the rennin-angiotensin system (7), inhibits vascular smooth muscle cell proliferation (8) CVDs are the major causes of mortality and morbidity in patients with RA (10) . RA was recently shown to be associated with a 1.48-fold increase in CVDs (11) and a 1.6-fold increase in CVD-related death (12) , compared to the general population.
Epidemiological studies demonstrated that traditional risk factors such as smoking, hypertension, dyslipidemia, diabetes, and obesity as well as the inflammatory burden of RA can cause premature atherosclerosis and eventually lead to CVD development. As mounting evidence indicating the immunoregulatory effect of vitamin D has prompted several studies investigating the association of hypovitaminosis D with the disease activity and outcomes of RA (13) . However, little attention has been given to the association of vitamin D deficiency with atherosclerosis or CVDs in patients with RA. Accordingly, the present study determined if vitamin D deficiency is a potential risk factor for carotid atherosclerosis assessed by carotid intima-meida thickness (CIMT) in patients with RA.
Materials and Methods

Study design and subjects
This cross-sectional study included 50 consecutive female RA patients (aged 18∼75 years) from a single outpatient rheuma- The concentrations of TC, TGs, and HDL-C were analyzed using an enzymatic colorimetric reagent (Roche Diagnostics, Zurich, Switzerland) and a P800 Module (Roche Diagnostics).
LDL-C value was calculated using the Friedewald formula. The following additional data were collected: disease duration, medication records, swollen joint count (SJC), tender joint count (TJC), general health, physical function, immunoglobulin M-rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP; U/mL) and previous history of type 2 diabetes mellitus and dyslipidemia. For RA patients treated with glucocorticoids (GCs), the cumulative dose (in prednisone equivalent) was calculated by multiplying the current daily dose by the number of days for which patients had received GCs since they were first prescribed. General health was assessed using a visual analogue scale (VAS) ranging form 0-100 and physical function was assessed using the Korean Version of health IQR: interquartile range, RF: rheumatoid factor, Anti-CCP antibody: Anti-citrullinated protein antibody, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, DAS28: disease activity score 28, GCs: glucocorticoids, K-HAQ: Korean Version of health assessment questionnaire, TNF-α: tumor necrosis factor-alpha, 25-OHD: 25-hydroxy vitamin D. assessment questionnaire (K-HAQ) (16) . Immunoglobulin M-RF was assessed by particle-enhanced immunoturbidometric assay (range 0∼14 IU/ml) and anti-CCP was measured using chemiluminescent microparticle immunoassay (range 0∼ 5 U/mL). Disease activity score (DAS) 28-ESR was calculated using the following formula (17):
On the same day of blood sampling, CIMT was measured using high-resolution ultrasonography (Philips HD 15, Bothwell, WA, USA) with a 7.5 to 12.5-MHz linear array transducer. The far walls on both sides of the common carotid artery, carotid bulb and internal carotid artery were visualized at the lateral and anterior-oblique angles. CIMT measurements were performed automatically using QLAB's CIMT quantification software (Philips Healthcare, DA Best, The Netherlands), which can enhance the consistency and reliability of measurement (18) . The mean of maximal CIMT from all carotid segments was collected from each study subjects. A CIMT ≥0.6 mm was considered as a maker of subclinical atherosclerosis (19, 20) . Carotid plaque was assessed in the common carotid artery, carotid bulb and internal carotid artery and was defined as a distinct protrusion of ≥50% from the adjacent wall into the vessel lumen. 
Statistical analysis
Results
A total of 50 female patients with RA were enrolled in this study. Their baseline characteristics and biomarker levels are summarized in Table 1 . Their mean±SD age was 56.0±11.2 Table 3 . Linear regression models for carotid intima media thickness in study subjects (Table 3 ). In addition, low serum 25-OHD levels were also significantly associated with increased CIMT in the multivariable regression models (data not shown).
Discussion
Little is known about the epidemiological association be- This study has some limitations that warrant further discussion. First, the explanatory power of our model is limited by the small sample size. In addition, because only 3 RA patients had carotid plaques, we could not investigate the association between carotid plaque and vitamin D deficiency.
Second, 48% of patients with RA in the present study had remission, with DAS-ESR scores less than 2.6 and there were few active RA patients. Thus, the present subjects may not represent of the entire RA population. Third, this study was a single center study, which could have led to a selection bias.
Conclusion
Vitamin D deficiency was significantly associated with increased CIMT in female patients with RA after adjusting for confounding factors in our study. Thus, the results suggest that hypovitaminosis D is a risk factor for subclinical atherosclerosis in patients with RA. Randomized controlled trials demonstrating that vitamin D supplementation reduces the risks of atherosclerosis or future CVDs in patients with RA are required to corroborate the present findings.
